Freenome agreed to go public via a $330 million SPAC merger as it prepares potential commercialization of its colorectal multi‑cancer screening test. The transaction includes a roughly $240 million PIPE commitment from healthcare investors and aims to fund late‑stage commercialization activities and regulatory positioning as the company seeks FDA clearance for SimpleScreen. CEO Aaron Elliott framed the IPO as timed to an inflection point for blood‑based screening; the capital will support market rollout if regulatory approvals are secured in 2026.